Immunome logo

Immunome

IMNM | NASDAQ
Chart Builder DCF Calculator
$17.61
-$1.16 (-6.18%)
At close: Nov 16, 2026, 4:00 PM ET
$17.69
+$0.08 (+0.45%)
After-hours: Nov 16, 2026, 7:30 PM ET
-6.18%

Rating

Updated: Nov 16, 2026
30.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #795/1021 (Top 78%)

Key Statistics

Market Data

Market Cap $2.08B
1D Range
17.55 19.15
52W Range
16.47 29.83

Valuation (TTM)

PE -6.65
PB 4.58
EV/EBITDA -5.84

Valuation (NTM)

Forward PE N/A
Forward PEG -0.59
Price Target $34.00
Loading financial charts...

Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United S...

Sector Healthcare
Industry Biotechnology
Employees 247
IPO Date Oct 2, 2020
Fiscal Year January - December

Latest News

Immunome Analysts Cut Their Forecasts After Q3 Results

6 days ago · benzinga.com

Immunome Analysts Cut Their Forecasts After Q3 Results
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 days ago · businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know

13 days ago · zacks.com

Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

13 days ago · zacks.com

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

15 days ago · businesswire.com

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

18 days ago · businesswire.com

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

22 days ago · businesswire.com

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

2 months ago · businesswire.com

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

3 months ago · businesswire.com

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing

3 months ago · marketbeat.com

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing

Earnings

Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$35.00
Upside
+98.75%
Buy (10)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.